Physician profile
Joshua Priddle
NPI 1154736346
$683.54
in general payments reported to CMS, 2019-2025
14 companies · $162 in 2025
The $162 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52.44 · 2020: $40.34 · 2021: $56.91 · 2022: $80.16 · 2023: $94.82 · 2024: $197 · 2025: $162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $453.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $124.34 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $105.65 | 2019-2025 | |
| Novo Nordisk INC | $102.08 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $59.31 | 2019-2022 | |
| Stryker Corporation | $49.16 | 2025 | Dart-Fire, Ortholoc 3di, Actishield |
| Merck Sharp & Dohme LLC | $47.91 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Lilly USA, LLC | $44.48 | 2020-2025 | Mounjaro, Zepbound |
| Amgen INC. | $30.88 | 2023 | Otezla, Repatha |
| Abbvie INC. | $26.26 | 2024 | |
| Lundbeck LLC | $24.47 | 2025 | Rexulti |
| Sumitomo Pharma America, INC. | $20.67 | 2025 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $19.50 | 2023 | Nuzyra |
| Exact Sciences Corporation | $15.17 | 2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $13.66 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Priddle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.